Bacteriological and clinical studies on biapenem in complicated urinary tract infections

Abstract

Bacteriological and clinical studies on biapenem (BIPM) were carried out, and the results were as follows.
1. Antimicrobial activity of BIPM
The MICs against clinical isolates from urine were determined and compared with those of imipenem (IPM), ceftazidime (CAZ) and piperacillin (PIPC).
The MIC₉₀ of BIPM was 10μg/ml for methicillin-sensitive Staphylococcus aureus [MSSA], 16μg/ml for methicillin-resistant S. aureus [MRSA].
Activity against S. epidermidis, Enterococcus faecalis and E. faecium was low, but similar to that of IPM, CAZ and PIPC.
Against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa, BIPM was superior to IPM, CAZ and PIPC.
Against Proteus mirabilis and indole-positive Proteus spp., BIPM was superior to IPM, and was similar to CAZ and PIPC.
2. Clinical efficacy of BIPM
In clinical study, BIPM was administered to 15 patients with complicated urinary tract infections (10 with cystitis and 5 with pyelonephritis), and the clinical effects and side effects were investigated. BIPM was administered at a dose of 300mg or 600mg twice a day for 5 days.
The clinical effects were evaluated according to the criteria proposed by Japanese UTI Committee for drug efficacy evaluation in 13 of the 15 patients.
The clinical response in the 13 evaluable cases with complicated UTI was excellent in 4, good in 7 and poor in 2, and the overall efficacy rate was 84.6%.
The bacteria elimination rate was 90.5% of 21 strains.
No subjective side effects or abnormal laboratory findings were observed.